Novo Nordisk A/S or Teva Pharmaceutical Industries Limited: Who Invests More in Innovation?

Novo Nordisk's R&D investment dwarfs Teva's by 2023.

__timestampNovo Nordisk A/STeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014137620000001488000000
Thursday, January 1, 2015136080000001525000000
Friday, January 1, 2016145630000002111000000
Sunday, January 1, 2017140140000001848000000
Monday, January 1, 2018148050000001213000000
Tuesday, January 1, 2019142200000001010000000
Wednesday, January 1, 202015462000000997000000
Friday, January 1, 202117772000000967000000
Saturday, January 1, 202224047000000838000000
Sunday, January 1, 202332443000000953000000
Monday, January 1, 202448062000000998000000
Loading chart...

In pursuit of knowledge

Innovation Investment: Novo Nordisk vs. Teva Pharmaceutical

In the competitive landscape of the pharmaceutical industry, innovation is key to staying ahead. Novo Nordisk A/S and Teva Pharmaceutical Industries Limited are two giants in this field, each with a distinct approach to research and development (R&D). Over the past decade, Novo Nordisk has consistently outpaced Teva in R&D investment. From 2014 to 2023, Novo Nordisk's R&D expenses surged by approximately 136%, peaking at over 32 billion in 2023. In contrast, Teva's investment in innovation has seen a decline, with a 36% drop over the same period, reaching just under 1 billion in 2023. This stark difference highlights Novo Nordisk's commitment to innovation, potentially driving its future growth and market leadership. As the pharmaceutical industry evolves, the emphasis on R&D will likely continue to shape the competitive dynamics between these two companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025